Novel mediators and biomarkers of thrombosis

Travis Sexton; Susan S. Smyth

doi:10.1007/s11239-013-1034-5

Novel mediators and biomarkers of thrombosis

Travis Sexton
, Susan S. Smyth

Internal Medicine

Producción científica: Article › revisión exhaustiva

9 Citas (Scopus)

Resumen

Spurred by advances in understanding the molecular basis of thrombosis, this issue of the Journal of Thrombosis and Thrombolysis is devoted to exploring aspects of novel paradigms and their potential impact on diagnosis and treatment. Complex interplay between blood and vascular cells, inflammation, and pro- and anti-coagulant pathways determines the formation and stability of arterial and venous thrombosis. A causal role for inflammation in coronary artery disease is currently being tested in large clinical trials. Basic science observations implicate inflammation in venous thromboembolic disorders and inflammatory processes, may have a similar influence on device thrombosis. In this article and throughout this issue of the Journal, we discuss biomarkers and mediators associated with arterial and venous thrombosis, atrial fibrillation, and other clinical scenarios.

Idioma original	English
Páginas (desde-hasta)	1-3
Número de páginas	3
Publicación	Journal of Thrombosis and Thrombolysis
Volumen	37
N.º	1
DOI	https://doi.org/10.1007/s11239-013-1034-5
Estado	Published - ene 2014

Nota bibliográfica

Funding Information:
Acknowledgments The authors thank Susan Quick for excellent editorial assistance. This work was supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000117 and TL1TR000115. TS was supported in part by T32HL091812 from the Heart Lung and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This material is also based on work supported in part by resources at the Lexington VA Medical Center.

Financiación

Acknowledgments The authors thank Susan Quick for excellent editorial assistance. This work was supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000117 and TL1TR000115. TS was supported in part by T32HL091812 from the Heart Lung and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This material is also based on work supported in part by resources at the Lexington VA Medical Center.

Financiadores	Número del financiador
National Institutes of Health (NIH)	TL1TR000115
National Heart, Lung, and Blood Institute (NHLBI)	T32HL091812
National Center for Research Resources
National Center for Advancing Translational Sciences (NCATS)	UL1TR000117

ASJC Scopus subject areas

Hematology
Cardiology and Cardiovascular Medicine

Acceder al documento

10.1007/s11239-013-1034-5

Otros archivos y enlaces

Citar esto

@article{3b32899a85194fef894745ec4ac406ef,

title = "Novel mediators and biomarkers of thrombosis",

abstract = "Spurred by advances in understanding the molecular basis of thrombosis, this issue of the Journal of Thrombosis and Thrombolysis is devoted to exploring aspects of novel paradigms and their potential impact on diagnosis and treatment. Complex interplay between blood and vascular cells, inflammation, and pro- and anti-coagulant pathways determines the formation and stability of arterial and venous thrombosis. A causal role for inflammation in coronary artery disease is currently being tested in large clinical trials. Basic science observations implicate inflammation in venous thromboembolic disorders and inflammatory processes, may have a similar influence on device thrombosis. In this article and throughout this issue of the Journal, we discuss biomarkers and mediators associated with arterial and venous thrombosis, atrial fibrillation, and other clinical scenarios.",

keywords = "Biomarkers, Inflammation, Mediators, Thrombosis",

author = "Travis Sexton and Smyth, \{Susan S.\}",

note = "Funding Information: Acknowledgments The authors thank Susan Quick for excellent editorial assistance. This work was supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000117 and TL1TR000115. TS was supported in part by T32HL091812 from the Heart Lung and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This material is also based on work supported in part by resources at the Lexington VA Medical Center.",

year = "2014",

month = jan,

doi = "10.1007/s11239-013-1034-5",

language = "English",

volume = "37",

pages = "1--3",

number = "1",

}

TY - JOUR

T1 - Novel mediators and biomarkers of thrombosis

AU - Sexton, Travis

AU - Smyth, Susan S.

N1 - Funding Information: Acknowledgments The authors thank Susan Quick for excellent editorial assistance. This work was supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000117 and TL1TR000115. TS was supported in part by T32HL091812 from the Heart Lung and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This material is also based on work supported in part by resources at the Lexington VA Medical Center.

PY - 2014/1

Y1 - 2014/1

N2 - Spurred by advances in understanding the molecular basis of thrombosis, this issue of the Journal of Thrombosis and Thrombolysis is devoted to exploring aspects of novel paradigms and their potential impact on diagnosis and treatment. Complex interplay between blood and vascular cells, inflammation, and pro- and anti-coagulant pathways determines the formation and stability of arterial and venous thrombosis. A causal role for inflammation in coronary artery disease is currently being tested in large clinical trials. Basic science observations implicate inflammation in venous thromboembolic disorders and inflammatory processes, may have a similar influence on device thrombosis. In this article and throughout this issue of the Journal, we discuss biomarkers and mediators associated with arterial and venous thrombosis, atrial fibrillation, and other clinical scenarios.

AB - Spurred by advances in understanding the molecular basis of thrombosis, this issue of the Journal of Thrombosis and Thrombolysis is devoted to exploring aspects of novel paradigms and their potential impact on diagnosis and treatment. Complex interplay between blood and vascular cells, inflammation, and pro- and anti-coagulant pathways determines the formation and stability of arterial and venous thrombosis. A causal role for inflammation in coronary artery disease is currently being tested in large clinical trials. Basic science observations implicate inflammation in venous thromboembolic disorders and inflammatory processes, may have a similar influence on device thrombosis. In this article and throughout this issue of the Journal, we discuss biomarkers and mediators associated with arterial and venous thrombosis, atrial fibrillation, and other clinical scenarios.

KW - Biomarkers

KW - Inflammation

KW - Mediators

KW - Thrombosis

UR - https://www.scopus.com/pages/publications/84895073579

UR - https://www.scopus.com/pages/publications/84895073579#tab=citedBy

U2 - 10.1007/s11239-013-1034-5

DO - 10.1007/s11239-013-1034-5

M3 - Article

C2 - 24356857

AN - SCOPUS:84895073579

SN - 0929-5305

VL - 37

SP - 1

EP - 3

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

IS - 1

ER -

Novel mediators and biomarkers of thrombosis

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto